- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.06. | Aelis Farma: Availability of the Description of the Share Buyback Program | 236 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 27.05. | Results of Aelis Farma Combined General Meeting of May 27, 2025 | 279 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 06.05. | Aelis Farma: Combined General Meeting of May 27, 2025: Availability of Preparatory Documents and Participation and Voting Procedures | 326 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 29.04. | Aelis Farma: Availability of the 2024 Universal Registration Document | 241 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 01.04. | Aelis Farma Reports Its 2024 Annual Financial Results and Confirms Its 2025 Outlook | 366 | Business Wire | 2024 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the results of the Phase 2b clinical... ► Artikel lesen | |
| 26.03. | Aelis Farma Announces the Final Analysis of the Landmark Phase 2B Clinical Trial in Cannabis Use Disorder (CUD) with the CB1-SSi AEF0117 | 408 | Business Wire | The purpose of this pioneering Phase 2B trial was to show that AEF0117 reduces cannabis use and to determine the endpoints and optimal dosage to be used in future studies. AEF0117 is the first... ► Artikel lesen | |
| 17.02. | Aelis Farma Announces Its 2025 Financial Calendar | 289 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| AELIS FARMA Aktie jetzt für 0€ handeln | |||||
| 18.11.24 | Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome | 357 | Business Wire | The CB1-SSi AEF0217 successfully met the safety (primary), pharmacokinetic (secondary) and efficacy (secondary and exploratory) objectives of this phase 1/2 performed in young adults with Down... ► Artikel lesen | |
| 26.09.24 | Aelis Farma: Availability of the 2024 Half-year Financial Report | 297 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year... ► Artikel lesen | |
| 25.09.24 | Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update | 392 | Business Wire | A solid cash position of €12.6 million at June 30, 2024, not including the gross amount of €4.5 million share offering which occurred at the end of July and other non-dilutive financing currently... ► Artikel lesen | |
| 04.09.24 | Indivior PLC: Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder | 475 | PR Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN... ► Artikel lesen | |
| 04.09.24 | Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD) | 441 | Business Wire | The main objective of this phase 2B study was to demonstrate that AEF0117 reduces cannabis use and to determine the endpoints as well as the optimal dosage of AEF0117 for use in future studies.... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,960 | -0,24 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Qiagen nach Zahlen von 54 auf 57 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Tycho Peterson attestierte dem... ► Artikel lesen | |
| EVOTEC | 6,356 | -2,37 % | Evotec-Aktie: Kurs heute im Minus (6,566 €) | Die Evotec-Aktie notiert heute etwas leichter. Das Papier kostete zuletzt 6,57 Euro. Heute hat sich an der deutschen Börse die Aktie von Evotec zwischenzeitlich um 3,13 Prozent verbilligt. Der Kurs... ► Artikel lesen | |
| DYNE THERAPEUTICS | 12,380 | -1,12 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,550 | +1,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BOLT PROJECTS | 8,910 | +4,82 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| BIONTECH | 97,00 | -0,05 % | BioNTech einigt sich mit Curevac, GlaxoSmithKline profitiert davon und Novo Nordisk steht zwischen Licht und Schatten | Die Pharmabranche bleibt eine schnelllebige Angelegenheit. Was gestern noch Überflieger war, hat es sich mittlerweile irgendwo im Kurskeller bequem gemacht. In den Augen der Anleger können die Aussichten... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,105 | -0,05 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| VALNEVA | 4,730 | -0,76 % | AKTIE IM FOKUS: Valneva schnellen hoch - Halbjahreszahlen treiben an | PARIS (dpa-AFX) - Robuste Geschäftszahlen zum ersten Halbjahr haben die Aktien von Valneva am Dienstag angetrieben. Die Papiere des französischen Impfstoffherstellers schnellten im frühen Handel um... ► Artikel lesen | |
| IMMUNOME | 10,280 | +3,32 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| ARS PHARMACEUTICALS | 14,540 | +0,48 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| RECURSION PHARMACEUTICALS | 5,765 | +2,22 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,690 | +0,91 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 4,520 | +1,80 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
| LENZ THERAPEUTICS | 37,870 | -7,43 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,820 | +3,33 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen |
AELIS FARMA SAS gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,405 (+34,47 %) liegt der Kurs bei 1,580 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AELIS FARMA SAS finden Sie auf Wallstreet Online.